Linked Life Data

10648380

Source:http://linkedlifedata.com/resource/pubmed/id/10648380

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10648380rdf:typepubmed:Citationlld:pubmed
pubmed-article:10648380lifeskim:mentionsumls-concept:C0080125lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0073243lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C1977882lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C1514468lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0920425lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:10648380lifeskim:mentionsumls-concept:C1711351lld:lifeskim
pubmed-article:10648380pubmed:issue3lld:pubmed
pubmed-article:10648380pubmed:dateCreated2000-2-24lld:pubmed
pubmed-article:10648380pubmed:abstractTextOne major obstacle to the effective treatment of cancer is to distinguish between tumor cells and normal cells. The chimeric molecules created by cancer-associated chromosomal abnormalities are ideal therapeutic targets because they are unique to the disease. We describe the use of a novel approach based on the catalytic RNA subunit of RNase P to destroy specifically the tumor-specific fusion genes created as a result of chromosome abnormalities. Using as a target model the abnormal BCR-ABL p190 and p210 products, we constructed M1-RNA with guide sequences that recognized the oncogenic messengers at the fusion point (M1-p190-GS and M1-p210-GS). To test the effectiveness and the specificity of M1-p190-GS and M1-p210-GS, we studied in vitro and in vivo effects of these RNA enzymes against BCR-ABL(p190) and BCR-ABL(p210), bearing in mind that both fusion genes share the ABL sequence but differ in the sequence coming from the BCR gene. We showed that M1-p190-GS and M1-p210-GS can act as sequence-specific endonucleases and can exclusively cleave target RNA that forms a base pair with the guide sequence (GS). We also demonstrated that when M1-p190-GS and M1-p210-GS were expressed in proper mammalian cell models, they abolished the effect of BCR-ABL by specifically decreasing the amount of the target BCR-ABL mRNA and preventing the function of the BCR-ABL oncogenes. These data clearly demonstrate the usefulness of the catalytic activity of M1-GS RNA to cleave specifically the chimeric molecules created by chromosomal abnormalities in human cancer and to represent a novel approach to cancer treatment.lld:pubmed
pubmed-article:10648380pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:languageenglld:pubmed
pubmed-article:10648380pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10648380pubmed:statusMEDLINElld:pubmed
pubmed-article:10648380pubmed:monthFeblld:pubmed
pubmed-article:10648380pubmed:issn0006-4971lld:pubmed
pubmed-article:10648380pubmed:authorpubmed-author:CobaledaCClld:pubmed
pubmed-article:10648380pubmed:authorpubmed-author:Sánchez-Garcí...lld:pubmed
pubmed-article:10648380pubmed:issnTypePrintlld:pubmed
pubmed-article:10648380pubmed:day1lld:pubmed
pubmed-article:10648380pubmed:volume95lld:pubmed
pubmed-article:10648380pubmed:ownerNLMlld:pubmed
pubmed-article:10648380pubmed:authorsCompleteYlld:pubmed
pubmed-article:10648380pubmed:pagination731-7lld:pubmed
pubmed-article:10648380pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:meshHeadingpubmed-meshheading:10648380...lld:pubmed
pubmed-article:10648380pubmed:year2000lld:pubmed
pubmed-article:10648380pubmed:articleTitleIn vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.lld:pubmed
pubmed-article:10648380pubmed:affiliationDepartment of Cell Growth and Differentiation, Institute of Microbiology and Biochemistry, CSIC/University of Salamanca, Salamanca, Spain.lld:pubmed
pubmed-article:10648380pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10648380pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10648380pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10648380pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10648380lld:pubmed